



(51) International Patent Classification:

A61K 38/17 (2006.01) A61P 13/00 (2006.01)
A61K 47/50 (2017.01) A61P 31/00 (2006.01)
A61P 9/00 (2006.01)

(21) International Application Number:

PCT/IB2023/000183

(22) International Filing Date:

06 April 2023 (06.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/328,210 06 April 2022 (06.04.2022) US

(71) Applicant: ABIONYX PHARMA SA [FR/FR]; 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR).

(72) Inventors: TUPIN, Cyrille; c/o Abionyx Pharma SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR). PEYROTTE, Constance; c/o Abionyx Pharma SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR). BARBARAS, Ronald; c/o

Abionyx Pharma SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR).

(74) Agent: HOFFMANN EITLE PATENT- UND RECHTSANWÄLTE PARTMBB, ASSOCIATION NO. 151; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID BINDING PROTEIN-BASED COMPLEXES




FIG. 1

(57) Abstract: Methods for treating leukocytosis, endothelial dysfunction, and carditis comprising administering to a subject a lipid binding protein-based complex.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*